Lucitanib (E-3810) is a potent and selective small molecule inhibitor targeting vascular endothelial growth factor receptors (VEGFR1/2/3) and fibroblast growth factor receptors (FGFR1/2). It has demonstrated anti-angiogenic and anti-tumor activity in preclinical studies, supporting its investigation in oncology research, particularly for cancers driven by these signaling pathways.
